Ignite Creation Date:
2024-05-06 @ 6:58 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05847036
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2023-04-07
Brief Title:
Profiles of Urinary Tract Infections in General Practice
Sponsor:
CNGE Conseil
Organization:
CNGE Conseil
Study Overview
Official Title:
Profiles of Urinary Tract Infections in General Practice a Prospective Multicentre Cohort Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PODIUM
Brief Summary:
Urinary tract infections UTIs are one of the most common bacterial infections managed in general practice they are the 2nd site of community-acquired bacterial infection after respiratory infections 4-6 million consultations per year in France
UTIs represent 15 of total antibiotic prescriptions in France Antibiotics recommended for UTIs except for cystitis are considered as critical highly generating bacterial resistances UTIs are a potential source of antibiotic resistance often inappropriate antibiotic prescriptions evolution of the resistance profiles of the bacteria involved emergence of multi-resistant strains
The first hypothesis is that there are other profiles of clinical UTI situations in general practice than typical cystitis or pyelonephritis including intermediate forms
The second hypothesis is that these intermediate forms of UTI are subject to longer durations of antibiotherapy and that probable explanatory factors need to be identified
UTIs represent 15 of total antibiotic prescriptions in France Antibiotics recommended for UTIs except for cystitis are considered as critical highly generating bacterial resistances UTIs are a potential source of antibiotic resistance often inappropriate antibiotic prescriptions evolution of the resistance profiles of the bacteria involved emergence of multi-resistant strains
The first hypothesis is that there are other profiles of clinical UTI situations in general practice than typical cystitis or pyelonephritis including intermediate forms
The second hypothesis is that these intermediate forms of UTI are subject to longer durations of antibiotherapy and that probable explanatory factors need to be identified
Detailed Description:
Urinary tract infections UTIs are one of the most common bacterial infections managed in general practice they are the 2nd site of community-acquired bacterial infection after respiratory infections 4-6 million consultations per year in France
UTIs represent 15 of total antibiotic prescriptions in France Antibiotics recommended for UTIs except for cystitis are considered as critical highly generating bacterial resistances UTIs are a potential source of antibiotic resistance often inappropriate antibiotic prescriptions evolution of the resistance profiles of the bacteria involved emergence of multi-resistant strains
Current guidelines classify UTIs as uncomplicated UTI cystitis and pyelonephritis and UTI at risk of complication cystitis pyelonephritis and male UTI 1-2 However in primary care pathologies are diagnosed at an early stage the clinical signs usually described by scientific societies are not always all found and the descriptions are not always adapted to the realities encountered in general practice 3-6 Some clinical situations do not fit into the systematic categories of the guidelines with intermediate forms such as pain in the lumbar fossae without fever cysphritis or other atypical presentations 3 The current literature in general practice highlights these issues the need for prospective cohorts in real-life practice to identify these profiles and develop more appropriate guidelines 3-6 Treatment for these intermediate forms is not obvious and is often empirical potentially longer antibiotherapies with possible worsening of antibiotic resistance 7
The first hypothesis is that there are other profiles of clinical UTI situations in general practice than typical cystitis or pyelonephritis including intermediate forms
The second hypothesis is that these intermediate forms of UTI are subject to longer durations of antibiotherapy and that probable explanatory factors need to be identified
UTIs represent 15 of total antibiotic prescriptions in France Antibiotics recommended for UTIs except for cystitis are considered as critical highly generating bacterial resistances UTIs are a potential source of antibiotic resistance often inappropriate antibiotic prescriptions evolution of the resistance profiles of the bacteria involved emergence of multi-resistant strains
Current guidelines classify UTIs as uncomplicated UTI cystitis and pyelonephritis and UTI at risk of complication cystitis pyelonephritis and male UTI 1-2 However in primary care pathologies are diagnosed at an early stage the clinical signs usually described by scientific societies are not always all found and the descriptions are not always adapted to the realities encountered in general practice 3-6 Some clinical situations do not fit into the systematic categories of the guidelines with intermediate forms such as pain in the lumbar fossae without fever cysphritis or other atypical presentations 3 The current literature in general practice highlights these issues the need for prospective cohorts in real-life practice to identify these profiles and develop more appropriate guidelines 3-6 Treatment for these intermediate forms is not obvious and is often empirical potentially longer antibiotherapies with possible worsening of antibiotic resistance 7
The first hypothesis is that there are other profiles of clinical UTI situations in general practice than typical cystitis or pyelonephritis including intermediate forms
The second hypothesis is that these intermediate forms of UTI are subject to longer durations of antibiotherapy and that probable explanatory factors need to be identified
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None